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Abstract
Background: Radiofrequency (RF) catheter ablation is a first-line therapy for patients with 
drug-refractory atrial fibrillation (AF). Complete isolation of electrical potentials at the ostium 
of pulmonary vein (PV) is a challenging procedure. There are different techniques and devices 
used for PV isolation (PVI). The objective of this study was to evaluate the efficacy and safety 
of PV ablation catheter (PVAC).
Methods: A total of 67 consecutive patients with paroxysmal and persistent AF were treated 
with the PVAC. The patients’ information were obtained from clinical charts. Follow-up was 
obtained by one day Holter monitoring at 2, 4, 6, 8, 10 and 12 months after ablation and ECG 
registration if any symptoms or arrhythmia occurred.
Results: The median follow-up duration was 16 months (IQR: 12–20 months). In the 
population which was available at follow-up (n = 60), 22 (36.7%) patients were in su-
stained sinus rhythm (SR) without anti-arrhythmic drugs (AAD). Overall 26 (43.3%) 
patients were in sustained SR with and without AAD. In the paroxysmal AF group,  
after a single PVAC ablation procedure (n = 39), 19 (48.7%) patients had sustained SR  
without AAD. In the persistent AF group (n = 15), after the single PVAC ablation, 2 (13.3%) 
patients had sustained SR without AAD.
Conclusions: PVI with PVAC is a safe procedure with 48.7% efficacy in patients with paroxy-
smal AF. The efficacy of PVAC in patients with persistent or long-standing persistent AF is not 
acceptable. (Cardiol J 2013; 20, 6: 618–625)
Key words: atrial fibrillation, pulmonary vein isolation, catheter ablation, 
arrhythmia
Introduction
Radiofrequency (RF) catheter ablation is 
a first-line therapy for patients with drug-refractory 
atrial fibrillation (AF) [1]. At the very beginning ab-
lation strategy consisted of focal ablation of triggers 
inside the pulmonary veins (PV) [2]. Because of 
PV stenosis, this method was modified to isolation 
of the PV by segmental isolation at the ostium of 
the veins [3]. Isolation of triggers within the PVs 
is the main treatment strategy in these patients 
[2]. Traditional techniques use a ring-shaped 
mapping catheter and an ablation catheter that 
applies RF energy in a unipolar fashion. Comple-
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te isolation of electrical potentials at the ostium 
of PV is a challenging procedure which requires 
a long learning curve. Strategies were evolving 
to include wide area encircling of the PV antrum 
using 3-dimensional mapping systems that could 
reconstruct anatomy of atrium to guide ablation 
and limit fluoroscopy time [4]. The evolution in 
ablation procedures led to increasingly complex 
and time consuming procedures and the need for 
high-technology equipment. Computed tomogra-
phy/magnetic resonance imaging integration, intra-
-cardiac echocardiography have been proposed as 
new tools for making the procedure easier. Little 
progress has been made in the development of 
ablation catheters. Traditionally, AF ablation is 
performed with a single-tip catheter with point-
-by-point ablation process. This technique requires 
a high degree operator skill, and the procedures 
are lengthy. Additionally, creating contiguous trans-
mural lesions is a difficult art. Therefore, there is 
a place for specialized RF ablation catheters spe-
cifically designed for AF ablation. The objective of 
this study was to evaluate the efficacy and safety 
of pulmonary vein ablation catheter (PVAC) (Med-
tronic, Ablation Frontiers, Carlsbad, CA, USA) in 
a Polish cardiologic centre which performs about 
200 AF ablations per year.
Methods
Patients
A total of 67 patients with paroxysmal or per-
sistent AF, who underwent elective PV isolation 
(PVI), were included in a retrospective registry. 
The characteristics of patients are presented in 
Table 1. Patients were admitted 24 h prior to the 
ablation procedure. Transesophageal echocardio-
graphy was performed to assess inter-atrial septum 
and to rule out intra-cardiac thrombus. Routine 
blood tests were performed, including electrolytes 
and cardiac enzymes.
Informed consent was obtained from all pa-
tients.
Ablation procedure
After vascular access through femoral veins 
was achieved, a steerable catheter was placed in 
the coronary sinus via the left femoral vein and 
a non-steerable catheter was placed in the right 
ventricular outflow tract. A transseptal puncture 
was performed using fluoroscopic imaging and 
pressure monitoring with the use of a long 8-Fr 
sheath (Biosense Webster PREFACE Sheath). 
After administering a heparin bolus (100 IU/kg), 
additional heparin of 1000 IU/h was given through-
out the procedure. The Preface sheath was then 
replaced by a deflectable, 12-Fr, long sheath (Flex-
Cath® Steerable Sheath) for advancing the PVAC 
catheter. The long sheath was perfused with 
heparinized saline solution. Thereafter, selective 
angiography of the PVs was performed with about 
40 mL of contrast agent in left anterior oblique and 
right anterior oblique projections.
The PVAC is a circular decapolar 9-Fr bi-
directional catheter with 3-mm-long platinum 
electrodes, inter electrode spacing of 3 mm, and 
a diameter of 25 mm. The PVAC is advanced over 
a 0.032-inch wire, which is positioned selectively in 
each PV or its branch to give support and stability 
to the ablation catheter. Selective cannulation of 
specific branches of the veins is very important to 
optimize catheter to wall contact during large com-
mon ostia isolation. With PVAC it was possible to 
map local signals, to stimulate and to apply RF over 
all or selected electrode pairs. The catheter is con-
nected to the dedicated RF generator — GENius 
(Medtronic Inc.). It delivers RF in a combination of 
1 or more of the 5 bipolar channels. Each electrode 
is supplied with a thermocouple, which permits 
a continuous local temperature monitoring. Target 
temperature during our procedures was 50–60oC 
with a maximum power of 8–10 W (8 W for 4:1 ratio, 
10 W for 2:1 ratio). The ratio 4:1 or 2:1 is proportion 
for bipolar/unipolar power delivery. In 4:1 ratio 
80% of energy is delivered in bipolar constellation 
and 20% in unipolar, in 2:1 ratio the percentages 
are 66.6% and 33.3%, respectively. If the created 
lesion was estimated to be nontransmural with the 
4:1 setting the RF ablation was set in a 2:1 bipolar/ 
/unipolar proportion. The lesions were estimated 
Table 1. Basic characteristics of population (n = 67).
Age 55.6 ± 10.3
Years from diagnosing AF 4.0 (2.0–8.0)
Age of AF diagnose 50.3 ± 10.1 
Persistent AF 25.4%
No. of AF episodes in month 4.5 (2–12)  
[n = 36]
Coronary artery disease 6.0%
Hypertension 68.7%
Diabetes mellitus 10.5%
Chronic heart failure 4.5%
Lone AF 26.9%
History of hyperthyroidism 11.9%
Hyperlipidemia 31.3% 
AF — atrial fibrillation
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to be transmural according to local ECG. Impulse 
duration was 60 s. We generally avoided premature 
termination of ablation which was stopped in case 
of strong pain or catheter dislodgement. After se-
veral RF applications over all electrode pairs, the 
PVAC was rotated around the ostium of PV, looking 
for the earliest pulmonary vein potential (PVP) 
to completely isolate the vein. Once the region 
of interest had been localized and perfect contact 
of the PVAC with antral tissue was achieved, RF 
was delivered only over selected electrode pairs. 
While performing ablation of large common ostia, 
electrode pairs that had suboptimal contact to the 
atrial tissue were deactivated, to avoid ineffective 
energy delivery. The end point was complete 
electrical isolation of all PVs. Figure 1 shows PVP 
during AF in the right superior pulmonary vein 
(RSPV) and Figure 2 shows potentials form of the 
ostium RSPV after complete isolation. Whenever 
it was possible, we confirmed the electrical block 
by advancing at least some PVAC electrodes into 
the PVs and demonstrating entrance and exit block. 
Figure 1. Pulmonary vein potentials during atrial fibrillation in right superior pulmonary vein; CS — coronary sinus 
catheter; PV — pulmonary vein ablation catheter; RVOT — catheter placed in right ventricle outflow tract.
Figure 2. Potential form the ostium right superior pulmonary vein after isolation; CS — coronary sinus catheter; 
PV — pulmonary vein ablation catheter; RVOT — catheter placed in right ventricle outflow tract.
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The protocol did not include routine confirmation 
of the PV isolation with a conventional circular 
diagnostic catheter. Figure 3 shows an example 
of a fluoroscopic image of the PVAC catheter over 
the antrum of the left superior PV. Differential pa-
cing was used while assessing the isolation of the 
lateral veins by pacing in the distal coronary sinus 
or left atrial appendage. Transthoracic echocardio-
graphy was performed 1 day after the procedure 
in all patients. Oral vitamin K antagonists (VKA) 
were discontinued 5 days before procedure, low-
-molecular-weight heparin was given from the day 
of discontinuation of VKA. VKA was introduced 
on the next day after ablation and continued for 
at least 3 months. Low-molecular-weight heparin 
was given until the international normalized ratio 
was between 2.0 and 3.0.
Follow-up
At discharge from hospital all the patients were 
encouraged to perform a 24 h Holter monitoring at 
2, 4, 6, 8, 10 and 12 months after ablation and ECG 
registration if any symptoms or arrhythmia occur-
red. The results were sent by mail. Antiarrhythmic 
drug (AAD) therapy was used in patients with 
early and recurrent episodes of symptomatic AF. 
Freedom from AF was defined as the absence of 
AF or atrial flutter or tachycardia lasting > 30 s. 
All patients who required a redo procedure 
within the follow-up period were classified as 
a primary failure of the initial ablation procedure. 
Patients were also followed-up by phone contact 
performed by physicians.
Statistical analysis
Categorical data were presented as percen-
tages and in case of subgroups the frequency was 
also noted. All continuous variables normally 
distributed were presented as mean value and stan-
dard deviation (SD). For non-normally distributed 
continuous variables median value and interquar-
tile range (IQR) were used. Normal distribution 
was accessed by Shapiro-Wilk test with an alpha 
level set at 0.05. Survival curves were made by 
Kaplan-Meier estimator, including patients with 
complete follow-up. To determine the risk factors 
of AF recurrence univariate and multivariable Cox 
proportional-hazards regression were performed. 
There were considered all pre-procedural, pro-
cedural and post-procedural factors. Statistical 
significance was considered for P-values lower 
than 0.05. Statistical analyses were made using 
SAS software, version 9.2. 
Results
Clinical characteristics of the patients
A total of 67 consecutive patients, aged 55.6 ± 
± 10.3 years, with paroxysmal (n = 50) or per-
sistent (n = 17) drug refractory AF, who were 
referred for PVI with PVAC between November 
2009 and December 2011, were included in the 
retrospective study. All patients had documented 
AF episodes with a median AF duration of 4 years 
(IQR: 2–8 years). Six patients from paroxysmal 
AF group had previous PVI procedure (4 mm 
non-irrigated ablation catheter, circular mapping 
catheter, with LocaLisa system). Those patients 
were excluded from analysis of success rates for 
single PVAC procedure. Clinical characteristics of 
the patients are summarized in Table 1. Echocar-
diographic recordings demonstrated an average 
left atrial size of 4.34 cm in the parasternal long-
-axis view.
Procedural success
The median total procedure time was 120 min 
(IQR: 105–155 min), including the advancement of 
femoral approach, transseptal puncture and pre- and 
post-ablation mapping of the PVs. PV angiography 
was performed prior to ablation. Nineteen patients 
had a left common trunk, 6 with persistent AF and 
13 with paroxysmal (Table 2). Five patients had 
Figure 3. Radioscopic image of the pulmonary vein 
ablation catheters (PVAC) catheter over the antrum 
of the left superior pulmonary vein ablation catheter; 
T-S sheath — transseptal sheath; LSPV — left superior 
pulmonary vein.
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right common trunk of PVs. Deployment of the 
PVAC was successful in all left and right PVs. In 29 
(43.3%) patients the superior vena cava (SVC) was 
isolated using the PVAC. The median duty cycled 
RF ablation time required to achieve complete PV 
isolation was 39 min (IQR: 31–50 min). The median 
total fluoroscopy time was 17 min (IQR: 14–21 min). 
Acute success of PVI confirmed by entrance block 
was achieved in 66 of 67 patients (98.5%) and in 
243 of 244 veins (99.6%).
Cardiac rhythm during follow-up
Seven (10.4%) patients were lost to follow-up. 
The median follow-up duration was 16 months 
(IQR: 12–20 months). The recurrence of AF was 
detected by 24 h Holter monitoring and/or by 
12 lead ECG performed in case of any arrhythmia 
symptoms occurrence. During the blanking period 
(3 months) 23 of 60 patients (38.3%) had recur-
rence of AF. In the population which was available 
at follow-up (n = 60), 22 (36.7%) patients were in 
sustained sinus rhythm (SR) without AAD. Overall 
26 (43.3%) patients were in sustained SR with and 
without AAD. In the paroxysmal AF group, after 
a single PVAC ablation procedure (n = 39), 19 
(48.7%) patients had sustained SR without AAD. In 
the persistent AF group (n = 15), after the single 
PVAC ablation, 2 (13.3%) patients had sustained 
SR without AAD. The single and all procedures 
clinical success of an ablation procedure during 
the whole follow-up period can be described in 
many ways (Table 3). Mean time of recurrence of 
AF was 3.8 months. Forty-seven (78.3%) patients 
declared a significant improvement in symptoms 
associated with arrhythmia, 9 (15%) patients did 
not see the difference and 4 (6.7%) patients decla-
red deterioration of symptoms. Of all the patients 
with recurrence 12 underwent one redo procedure 
Table 2. Procedural data.
Parameters Median (IQR)  
or percent
Time of procedure [min] 120 (105–155)
Time of X-ray [min] 17 (14–21)
Mean duty cycled radiofrequency  
ablation time [min]
39 (31–50)
Presence of common trunk of PV 34.3%
Complete isolation of PV 99.6%
Isolation of vena cava superior 43.3%
Presence of patient foramen ovale 29.7%
Cardioversion during AF procedure 3%
Procedure performed during AF 37.3% 
AF — atrial fibrillation; PV — pulmonary vein
Table 3. Overall efficacy by definitions of success in patients with paroxysmal and persistent AF after  
a PVAC procedure and after redo procedures.
Definition Success rate,  
no. (%)
Absence of AF/AFL/tachycardia, and patients were off class I or III AADs in  
whole group after single PVAC procedure
21/54 (38.9%)
Absence of AF/AFL/tachycardia, with or without class I or III AADs in  
whole group after single PVAC procedure
24/54 (44.5%)
Absence of AF/AFL/tachycardia, and patients were off class I or III AADs in  
paroxysmal AF group after single PVAC procedure
19/39 (48.7%)
Absence of AF/AFL/tachycardia, and patients with or without class I or III AADs in  
paroxysmal AF group after single PVAC procedure
21/39 (53.8%)
Absence of AF/flutter/tachycardia, and patients were off class I or III AADs in  
persistent AF group after single PVAC procedure
2/15 (13.3%)
Absence of AF/AFL/tachycardia, and patients with or without class I or III AADs in  
persistent AF group after single PVAC procedure
3/15 (20%)
Absence of AF/AFL/tachycardia, and patients were with or without class I or III AADs in 
whole group after all procedures (LocaLisa, PVAC, CARTO)
36/60 (60%)
Absence of AF/AFL/tachycardia, and patients were with or without class I or III AADs in  
paroxysmal AF group after all procedures (LocaLisa, PVAC, CARTO)
29/45 (64.4%)
Absence of AF/AFL/tachycardia, and patients were off I or III AADs in  
paroxysmal AF group after all procedures (LocaLisa, PVAC, CARTO)
23/45 (51.1%)
Absence of AF/AFL/tachycardia, and patients were with or without class I or III AADs in  
persistent AF group after all procedures (LocaLisa, PVAC, CARTO)
7/15 (46.7%)
Absence of AF/AFL/tachycardia, and patients were off I or III AADs in  
persistent AF group after all procedures (LocaLisa, PVAC, CARTO)
3/15 (20%)
AADs — anti-arrhythmic drugs; AF — atrial fibrillation; AFL — atrial flutter; PVAC — pulmonary vein ablation catheters
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with CARTO system and 2 of them underwent 
2 redo procedures. The overall success rate including 
redo procedures is 60% (36 of 60 sustained in SR 
with and without AAD).
Complications
There was 1 patient with stroke 1 day after the 
procedure (left upper limb paresis withdrawn on 
the next day). Symptoms withdrawn on the second 
day. In other patient there was cardiac tamponade/ 
/perforation (pericardial effusion up to 2 cm noticed 
during the procedure, which did not require the dra-
inage) and also transient ischemic attack (TIA) epi-
sode at the same time. The patient’s condition was 
stable, the blood pressure was 90/60 mm Hg. That 
is why we did not decide to perform the drainage. 
We administered 50 mg of protamine sulphate i.v. 
which is maximal dosage and the amount of fluid 
in pericardium stopped increasing. The symptoms 
of TIA (right upper limb paresis) withdrawn in 2 h.
Univariate and multivariate analyses
In the univariate Cox regression analysis the 
following pre-procedural, procedural and post-
-procedural factors were associated with the outco-
me after isolation of PVs with PVAC: isolation of 
SVC, history of chronic heart failure, episode of 
AF during the hospitalization after the procedure 
and also performing the ablation procedure during 
AF (Table 4).
After backward elimination multivariate Cox-
-regression analyses of pre-procedural, procedural 
and post-procedural factors did not show statisti-
cally significant correlations.
Discussion
The present data describe a consecutive group 
of 60 patients with complete follow-up, whose 
median is 16 months, after documented acute suc-
cess PVI by phased RF energy with the decapolar 
PVAC. Arrhythmia follow-up was performed with 
ECGs and 24 h Holter. The data show an overall 
freedom from AF or any other left atrial arrhythmia 
with and without AADs in 44.5% of patients after 
a single procedure with PVAC. Figure 4 presents 
the Kaplan-Meier curve demonstrating time to first 
AF recurrence after a single treatment with PVAC 
for paroxysmal and persistent AF.
Procedure performance of the PVAC
Generally, the performance of the PVAC ca-
theter seems at least comparable to the other single 
shot devices. Using the high density mesh ablation 
(HDMA) catheter, Mansour et al. [5] showed efficacy 
in electrical isolation of 63% of the PVs and 40% of 
the patients after a mean of 12 min of ablation time 
for each vein. Data concerning the cryoballoon sho-
wed that successful isolation of the PVs was possible 
in up to 92.5% of the veins and 83% of the patients 
[6]. All these devices concentrate on transforming 
ablation of paroxysmal AF into a straightforward 
procedure: PVI with a minimum of applications in 
a minimum of time, with a minimum of catheters, 
without mapping tools, and all this without decrea-
sing success rate or increasing complication rates.
We consistently validated the acute endpoint 
of PV isolation using the PVAC catheter in com-
Table 4. Results of univariate Cox proportional hazard regression for AF recurrence.
Factor Hazard ratio 95% CI P
Isolation of vena cava superior 0.45 0.22–0.94 0.0324
History of chronic heart failure 5.18 1.45–18.57 0.0115
AF during hospitalization after procedure 2.84 1.44–5.59 0.0025
Procedure performed during AF 2.21 1.12–4.62 0.0221
AF — atrial fibrillation; CI — confidence interval
Figure 4. Kaplan-Meier curve demonstrating time to first 
atrial fibrillation recurrence after a single treatment with 
pulmonary vein ablation catheters for paroxysmal and 
persistent atrial fibrillation.
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bination with dedicated differential pacing and 
observed that cumulative PVAC ablation resulted 
in electrical isolation of 98.5% of the patients 
and 99.6% of veins. Boersma et al. [7] performed 
validation with a circular mapping catheter in the 
initial 19 patients and reported 100% isolation. 
However they did not perform differential pacing 
to differentiate potentials on the mapping catheter. 
In these patients PVI assessment was based only 
upon PVAC recordings and reported to be 100%. 
Other authors suggest using steerable sheath, en-
hanced fluoroscopy, different guidewire positions in 
different side branches of the PVs, and registration 
of ostial potentials to obtain high isolation rates 
with the PVAC [8]. They also hypothesize that the 
use of the PVAC catheter by its design results in 
general in an ostial ablation. This is also observed 
with the HDMA catheter and the cryoballoon [9, 
10]. However, in case of a common ostium or when 
early branching is present, the guidewire can be 
positioned in different side branches of the PV 
resulting in different PVAC positions, creating 
overlapping ablation lines that as a whole result 
in a more wide circumferential PVI [8].
The PVAC is a combination of a mapping and 
ablation tool in 1 catheter. The cryoballoon tech-
nology has no mapping capabilities. Therefore, 
this ablation approach requires a second circular 
mapping catheter and multiple catheter exchanges. 
The only other single-shot device which combines 
diagnostic and therapeutic tools is the HDMA 
catheter. Mansour et al. [5] presented that 12% of 
the veins which seemed isolated on the HDMA, 
were not isolated on a regular circular mapping 
catheter. The other study showed that PVAC has 
a diagnostic accuracy of 95% [8]. Authors suggested 
that bipolar electrograms are less detailed (most 
likely due to larger electrode size) but allowed to 
correctly diagnose PVPs. To obtain high diagnostic 
accuracy with the PVAC catheter authors advocate: 
to torque the PVAC catheter within the PVs, to 
annotate baseline PVPs at fixed fluoroscopic refe-
rences before any RF delivery, and to apply limited 
pacing maneuvers [8]. In our procedures we were 
mapping according to those tips.
The advantage of PVAC procedure which is 
presented in other publications is the reduction of 
time of procedure and also the time of fluoroscopy 
[11]. In other study comparing efficacy of PVAC vs. 
CARTO procedure AF recurrence was documented 
in 23% and 29% of patients in the PVAC and CARTO 
groups, respectively (p = 0.8), they also found 
significantly shorter procedural and fluoroscopic 
times in the PVAC group (p < 0.0001) [12].
The incidence of left common  
pulmonary vein (LCPV)
There is a variation in the percentages of 
LCPV between large studies, ranging from 13% to 
29% [13–17]. In our population 34.3% of patients 
were with LCPV. The results of the statistical ana-
lysis show that the presence of LCPV in our cohort 
did not have a significant effect on the outcome of 
PVAC ablation.
Chronic success of procedure
The long-term success of AF procedure accor-
ding to the HRS/EHRA/ECAS expert consensus 
statement of 2012 is defined as freedom from 
AF/atrial flutter/atrial tachycardia recurrences 
following the 3-month blanking period through 
a minimum of 36 months of follow-up from the date 
of the ablation procedure in the absence of Class I 
and III AAD therapy [1]. The PVAC procedure has 
been launched in our center in November 2009 so 
there is no data available for such a long follow-up. 
However, in comparison to other available publi-
cations on PVAC, our median follow-up period of 
16 months is a big achievement [7, 8, 11, 13]. There 
is information about late recurrences which are 
defined as a recurrence of AF 12 months or more 
after ablation (Episodes of atrial tachycardia or 
atrial flutter should also be classified as a “recur-
rence”.) [1]. The single and all procedures clinical 
success of an ablation procedure during the whole 
follow-up can be described in many ways (Table 3). 
According to the actual HRS/EHRA/ECAS expert 
consensus statement on AF the minimal chronic 
acceptable success rate for paroxysmal AF at 
12-month follow-up for a clinical trials is 50% off 
AAD therapy including a pre-specified blanking pe-
riod. In our population of patients with paroxysmal 
AF we achieved 48.7% success rate without AADs 
after a single PVAC procedure and 51.1% success 
rate after all PVI procedures, however, the design 
of monitoring allows for recurrent AF events to 
be underdetected (particularly if they are asymp-
tomatic) compared to studies that use longer-term 
continuous monitors. The success rate meets the 
criteria by slimmest of margins, with the possibility 
of underdetection of AF recurrence. The minimal 
chronic acceptable success rate for persistent AF 
at 12-month follow-up for a clinical trials is 40% 
and for longstanding persistent is 30% off AAD 
therapy including a pre-specified blanking period. 
In our group with persistent AF the success rate 
for single PVAC procedure off AADs was 13.3% and 
after PVAC and redo procedure 20%. That is why 
based on our results we decided to perform PVAC 
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procedures only for patients with paroxysmal AF. 
Our results are quite similar to data presented by 
Mulder et al. [17] of 2 year follow-up of patients 
with paroxysmal AF treated with PVAC which 
shows 55% success rate after 1 year and decrease 
to 49% after 2 years in patients off AADs. Tho-
se results are different from those observed in 
studies with shorter follow-up. Beukema et al. 
[13] (n = 102) showed a 61% success rate with 
PVAC at 1 year. In a 6-month follow-up on patients 
with paroxysmal AF, Boersma et al. [7] (n = 98) 
demonstrated an 83% success with PVAC, while 
Wieczorek et al. [18] (n = 73) showed a success 
rate of 86%.
Complications
In our group we a observed 3% risk of throm-
bo-embolic events (2 patients of 67). The incidence 
of thrombo-embolism associated with AF ablation 
is reported to be between 0% and 7% [1, 19–23]. 
The rate of cardiac tamponade reported in Upda-
ted Worldwide Survey on the Methods, Efficacy, 
and Safety of Catheter Ablation for Human Atrial 
Fibrillation is 1.3% [24]. In our group the rate was 
1.5% (1 of 67 patients).
Conclusions
PVI with PVAC is a safe procedure with 48.7% 
efficacy in patients with paroxysmal AF. The effi-
cacy of PVAC in patients with persistent or long-
-standing persistent AF is not acceptable.
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